VALEANT PHARMACEUTICALS INTL's ticker is VRX and the CUSIP is 91911K102. A total of 365 filers reported holding VALEANT PHARMACEUTICALS INTL in Q3 2016. The put-call ratio across all filers is 0.92 and the average weighting 0.5%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q1 2018 | $1,000 | -99.6% | 56 | -99.5% | 0.00% | -100.0% |
Q4 2017 | $224,000 | +366.7% | 10,768 | +222.0% | 0.02% | +300.0% |
Q3 2017 | $48,000 | -4.0% | 3,344 | +15.8% | 0.01% | -28.6% |
Q2 2017 | $50,000 | -32.4% | 2,887 | -57.2% | 0.01% | -36.4% |
Q1 2017 | $74,000 | +572.7% | 6,746 | +1347.6% | 0.01% | +450.0% |
Q3 2016 | $11,000 | +266.7% | 466 | +180.7% | 0.00% | +100.0% |
Q2 2016 | $3,000 | -25.0% | 166 | 0.0% | 0.00% | 0.0% |
Q1 2016 | $4,000 | -63.6% | 166 | +50.9% | 0.00% | -75.0% |
Q4 2015 | $11,000 | -87.6% | 110 | -77.9% | 0.00% | -85.2% |
Q3 2015 | $89,000 | -85.3% | 498 | -81.2% | 0.03% | -84.8% |
Q2 2015 | $604,000 | +8.6% | 2,647 | -5.8% | 0.18% | +15.6% |
Q1 2015 | $556,000 | +12.1% | 2,809 | -11.6% | 0.15% | -0.6% |
Q4 2014 | $496,000 | +118.5% | 3,177 | +76.2% | 0.16% | +61.5% |
Q2 2014 | $227,000 | +8.6% | 1,803 | +13.8% | 0.10% | -11.1% |
Q1 2014 | $209,000 | +945.0% | 1,584 | +842.9% | 0.11% | +980.0% |
Q4 2013 | $20,000 | – | 168 | – | 0.01% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
ACCIPITER CAPITAL MANAGEMENT, LLC | 2,373,210 | $47,796,000 | 39.06% |
Claren Road Asset Management, LLC | 77,527 | $1,561,000 | 18.46% |
Okumus Fund Management Ltd. | 4,242,012 | $85,434,000 | 14.79% |
Chou Associates Management | 1,446,843 | $29,139,000 | 11.12% |
FARLEY CAPITAL L.P. | 307,458 | $6,192,000 | 9.65% |
HAP Trading, LLC | 3,129,700 | $112,397,000 | 6.58% |
Pershing Square Capital Management | 21,591,122 | $434,845,000 | 5.79% |
NORTH TIDE CAPITAL, LLC | 2,500,000 | $50,350,000 | 5.61% |
Convector Capital Management, LP | 192,000 | $3,867,000 | 5.34% |
Nebula Capital Management, LP | 31,770 | $640,000 | 5.07% |